AKT1 and colonic neoplasm: MDR1 and AKT expression decreased with increasing anlotinib concentration.<h4>Conclusion</h4>Anlotinib suppressed the proliferation of 5-FU-resistant colon cancer cells by preventing entry into S phase, thus sensitizing cells to 5-FU.